A review of the Glioblastoma
Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
2 List of Figures 9 2 Glioblastoma
Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Introduction 10 2.
"reoccur because every cell that is left behind has the ability to start all over again," Verma said.
And that explains why Gahbauer's clinical trials will focus on 20 or 25 patients with glioblastoma
multiforme; this brain tumor, which he notes currently accounts for about 2 percent of all cancer deaths in the United States, usually brings death within six months of diagnosis.
Avastin is currently approved in the United States for the treatment of adults with glioblastoma
who have progressive disease following prior therapy.
ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma
Interim Analysis of EF-14; Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma
Multiforme (GBM) Presenter: Roger Stupp MD, Director, University Hospital Cancer Center, University of Zurich, Zurich, Switzerland
Kaur noted that CCN1 helps regulate cellular functions that include adhesion, migration, and proliferation, and that it is overexpressed in 68 percent of glioblastoma
The trial was designed as a randomized controlled phase II proof of concept study in GBM, which is an exception in phase II development, but in this way it was clearly demonstrated to our investors and potential licensing partners that APG101 is efficacious and offers a new treatment option for glioblastoma
patients,' said Dr Harald Fricke, Chief Medical Officer of Apogenix GmbH.
Analyses of PRiDe, a registry of 457 recurrent glioblastoma
patients, demonstrate that patients treated with the NovoTTF-100A System at their first and second recurrences had median overall survivals of 20.
Zhongming Zhao and colleagues at Vanderbilt University, in Tennessee, explain how problems that occur during the transcription of the genetic code for making proteins may play a role in the formation of a glioblastoma
As part of the expanded collaboration, Merck has agreed to support MDxHealth's development and regulatory activities for the MGMT test and, after regulatory approval, the coordinated launch together with cilengitide in glioblastoma